News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
Content Sharing
JD HEALTH Reaches Strategic Cooperation with Eli Lilly China
JD HEALTH (06618.HK) officially entered into a strategic cooperation agreement with Eli Lilly China on 29 August, as announced by JD HEALTH. Both parties will fully leverage their ...
Reset
Send
The window will close in 5 seconds
JD HEALTH Reaches Strategic Cooperation with Eli Lilly China
Close
Recommend
12
Positive
22
Negative
5
 
 

JD HEALTH (06618.HK)  -0.550 (-0.854%)    Short selling $167.06M; Ratio 19.494%   officially entered into a strategic cooperation agreement with Eli Lilly China on 29 August, as announced by JD HEALTH.

Both parties will fully leverage their complementary advantages in ways like brand, product, channel, technology and services to jointly build an integrated management model of 'drug accessibility + health popular science + digital services' focusing on chronic diseases such as overweight, obesity, diabetes and alopecia areata, aiming to create an innovative one-stop chronic disease management solution, so as to continuously improve patients' treatment accessibility and health management levels.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-09-05 16:25.)

Related NewsCLSA Raises ALI HEALTH's TP to HKD6.5; Original/ Innovative Drugs See Strong Sales & Sustained Growth

AASTOCKS Financial News
Website: www.aastocks.com

Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.